Agios Pharmaceuticals, Inc. (AGIO) key performance indicators and operating metrics (13 metrics) from SEC EDGAR filings, earnings calls, and investor decks. First-party data.
| Metric | Latest Value | Period |
|---|---|---|
| Ex-US Net Revenue | 1.90 | FY2026-Q1 |
| Net product revenue from ex-U.S. sales of PYRUKYND | 1.9M | FY2026-Q1 |
| Cost of sales | 1.32M | FY2026-Q1 |
| Net (Loss) Income1 | -99.11M | FY2026-Q1 |
| Loss from Operations | -110.03M | FY2026-Q1 |
| Net product revenue from U.S. sales of PYRUKYND | 16M | FY2025-Q4 |
| Research and Development Expenses | 88.1M | FY2025-Q4 |
| Selling, General and Administrative Expense | 51.6M | FY2025-Q4 |
| Prescription Enrollment Form Completions (United States) - Total | 262.00 | FY2025-Q3 |
| Unique prescribers in U.S. | 227.00 | FY2025-Q3 |
| Patients on therapy (net patients) (United States) | 142.00 | FY2025-Q2 |
| TEAEs leading to treatment discontinuation - mitapivat | -4.71 percent | FY2025-Q1 |
| TEAEs leading to treatment discontinuation - placebo | -0.71 percent | FY2025-Q1 |
Back to AGIO overview · AGIO earnings · AGIO holders
Data sourced from U.S. SEC EDGAR filings, earnings call transcripts, and investor decks. Not personalized investment advice.